Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333478 | 0.91 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL4428020 | 0.90 | KIT (0.47) | ALDH1A1LMNASMN1; SMN2MEN1POLB | |
| SCHEMBL4325183 | 0.90 | HSD11B1 (0.46) | ALDH1A1LMNASMN1; SMN2MEN1POLB | |
| SCHEMBL4319443 | 0.88 | ALDH1A1 (0.49) | ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL4321247 | 0.86 | ALOX15 (0.46) | ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL4326491 | 0.86 | MEN1 (0.59) | ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL4317911 | 0.85 | L3MBTL1 (0.57) | ALDH1A1 | |
| SCHEMBL4419799 | 0.82 | ALDH1A1 (0.48) | ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL4320933 | 0.80 | SORD (0.41) | ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL4319182 | 0.80 | ALDH1A1 (0.62) | ALDH1A1LMNASMN1; SMN2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009143404-A1 | PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION | WYETH (US) | 2009-11-26 | — | — | WO | claimed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | ALDH1A1 3104/4885LMNA 4354/4885SMN1; SMN2 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.